As such, testing for KRAS mutations is nowadays standard practice in the management of CRC according to treatment guidelines, helping to personalize therapy and avoid ineffective treatments, thereby improving patient outcomes [11,12]. This evidence concerns the gene KRAS and colorectal carcinoma.